Health and FitnessMedical

Migraine Treatment Market

Migraine Treatment Market Is Expected to Witness Rapid Growth in Coming Years

A prevalent and incapacitating brain condition is migraine. 4.4% of all general practitioner visits, over 5% of all medical hospital admissions, and more than 20% of neurology outpatient appointments are for headaches. At some time in their life, 20% of individuals will experience a migraine; epidemiological studies show that 4.5% of people in Western Europe experience headaches at least 15 days a month; and international studies imply that 1% of people worldwide experience chronic migraine.

According to Data Bridge Market Research, the market for Migraine Drugs Market treatments, which was valued at USD 2.38 billion in 2021, is projected to soar to USD 4.67 billion by 2029 and have a CAGR of 8.80% from 2022 to 2029. The market report created by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework in addition to market insights like market value, growth rate, market segments, geographic coverage, market players, and market scenario.


A debilitating neurological condition called migraine is characterized by recurring, intense headache attacks that can last up to three days. The typical unilateral headaches might last anywhere from four hours to three days. Pain is usually associated with other symptoms such as nausea, vomiting, heightened sensitivity to sound (phonophobia), light sensitivity (photophobia), tingling or numbness in the legs or extremities, sweating, and diarrheic.

Factors driving the growth of the target market

The expanding knowledge of innovative medication classes and the global increase in migraine disorders are two elements boosting the target market’s growth. Additionally, the introduction of calcitonin gene-related peptide (CGRP) is anticipated to fuel this industry’s expansion. An acute and recurrent kind of headache known as a migraine is also accompanied with phonophobia, photophobia, and nausea. Genetic causes are the cause of the illness. A migraine episode can, however, be brought on by emotional imbalances including despair, stress, worry, shock, and enthusiasm.

In adults without a history of any other medical conditions, there are a number of drug solutions for treating and preventing migraines, but they come with serious side effects as well, including weight fluctuations, nausea, and dizziness. Sumatriptan is the safest therapeutic choice for pregnant women, and anticonvulsant medications are not advised. The U.S. Food and Drug Administration’s approval of a new class of medications created specifically to treat migraines, however, has had a favorable impact on the market.

For more visit

Further key findings from the report suggest

  • Current research focuses on novel action routes including CGRP-based receptor and ligand inhibition, corticotropin receptor antagonism, and nitrous oxide inhibition. The approval of CGRP monoclonal antibodies is one of the major developments in the preventative business.
  • With the introduction of Aiming, Amgen and Novartis are the first movers in the CGRP market and would stand to gain. The development of the target product would also benefit from a good reimbursement environment and an easy-to-use pen-device administration of the medicine. Following its debut in July 2020 in Europe and May 2020 in North America, the medicines got favorable reviews from doctors and other healthcare professionals.
  • In a market that is anticipated to be crowded and competitive with CGRP mAbs from Eli Lilly and Company and Teva Pharma, the introduction of Aimovig at a lower-than-anticipated price would improve patient access and support the sales of therapies in the preventative migraine arena.


The neurologic symptoms of COVID-19 suggest that the virus entered the nervous system by the olfactory groove or the bloodstream. Numerous studies have connected cardiac and pulmonary diseases to COVID-19 mortality. Additionally, migraine patients are more likely to experience poor COVID-19 results due to the increased burden of vascular problems caused by migraine. Acute COVID-19 symptoms such as fever, trouble sleeping, and dehydration might cause a migraine episode. Males were more likely to get COVID-19 headaches, which were described as pulsating, pressing, or stabbing in nature, often bilateral, lasting longer, and being resistant to analgesia. This renders those who suffer from migraines especially susceptible to the pandemic’s long-term and indirect effects, such as depression, fatigue from the virus, and anxiety.

About Us

A pioneer in cutting-edge formative research is Data Bridge Market Research. We take satisfaction in providing data and analysis to both new and current customers that are appropriate for their objectives. The report may be altered to incorporate refurbished market and product base analysis. The clinical trial outcomes data, literature research, and pricing trend analysis of target brands’ prices in new countries (ask for a list of countries). Technology-based analysis to market portfolio strategies may be used to assess market analysis of target rivals. In the structure and data type you choose, we may include as many rivals as you need. Additionally, our team of analysts can help you or supply you with data in Factbook or raw, unprocessed Excel pivot tables.


For more articles visit


Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button